BPK-29 |
Katalog-Nr.GC34502 |
BPK-29 ist ein spezifischer Ligand, der die atypischen Wechselwirkungen zwischen dem nukleÄren Rezeptor NR0B1 und dem Protein (wie RBM45 und SNW1) durch kovalente Modifikation von C274 unterbricht. BPK-29 beeintrÄchtigt das verankerungsunabhÄngige Wachstum von KEAP1-mutierten Krebszellen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2143467-62-1
Sample solution is provided at 25 µL, 10mM.
BPK-29 is a covalent small molecule that disrupts NR0B1 complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells[1].
BPK-29 substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers[1].
[1]. Woodruff TM,et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol. 2008 Dec 15;181(12):8727-34.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *